Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The Insomnia market in Europe, the Middle East, and Africa (EMEA) is marked by a growing concern for sleep disorders and an increasing awareness of insomnia-related issues. As a result, the market dynamics within these regions are undergoing significant changes.
Lately, insomnia has become a common sleep disorder with most inhabitants in EMEA being victims. The result of insomnia, on individuals' health, labor efficiency and quality of life is what interests the market participants to make an innovation in the unique solutions.
In short, overall healthcare expenditure in whole EMEA region grew at the same pace which resulted in extra investment into R&D in the field of insomnia treatments. This dramatic increase in financial support is leading to inventions and improved technologies among the relevant market players.
The companies that specialize in pharmaceutical drugs remain the most powerful players in the EMEA insomnia market. Aid sleep drugs and medical means covering drugs which no doubt remain be the most therapy means and share big market revenue among patients and healthcare providers.
In addition to drugs, there is a high due respect for non-pharmaceutical echolons too. CBT-I is gaining traction in cognitive behavioral therapy which can be used alongside the relaxation techniques and the lifestyle modifications which are being taken to control sleep disorders in patients.
With the help of technology, we can see that there has been a great impact on the insomnia industry. Wearable devices, intelligent mattresses and mobile applications developed to watch and improve the sleep cycle are getting more popular to give the chance to the consumers to create themselves both acceptable and personalized solutions.
Differences in healthcare base and proclivities for sleep conditions among the different regions convey the regional differentiation of EMEA insomnia market. Some places may be characterised by a fast diffusion of innovation in medical technologies, on the other hand, there are areas with infrastructural problems that limit access to the newest treatments.
Governments in EMEA region realise more and more that insomnia is not just a problem of an individual. Instead, it may be considered as a matter of public health. Regulatory systems and undertakings are being introduced to maintain the integrity and the efficiency of sleep aid medical treatments which creates a favourable environment ripe for a budding market.
The adoption of telemedicine for sleep consultations and remote monitoring of sleep patterns is gaining momentum. This trend is particularly significant in remote or underserved areas, where access to specialized healthcare services may be limited.
The EMEA insomnia market is characterized by intense competition among pharmaceutical companies, tech startups, and healthcare providers. Companies are striving to differentiate themselves by offering innovative products, personalized solutions, and enhanced patient experiences.
Europe Insomnia Market Highlights:
EMEA Insomnia Market Overview
The Europe,The Middle East And Africa Insomnia Market is expected to reach USD 1.9 Billion by 2032 at 3.3% CAGR during the forecast period 2023-2032. Insomnia a sleeping disorder caused by unhealthy sleep habits of a person. Medical conditions that may lead to insomnia are chronic pain, neurological conditions (Parkinson's disease), arthritis, nasal/sinus allergies, gastrointestinal problems, low back pain endocrine problems, asthma and other conditions. It is found to be prevalent among women than in men which may be the results of stress.
The Increasing incidence of neurological disorders like Parkinson’s disease favor the growth of this market. The market of insomnia in Europe, the Middle East and Africa is increasing due to increasing insomnia owing to lifestyle changes and use of sleeping pill. Mental stress related to work or other personal issues is found to be another cause leading to insomnia thus favouring the growth of market. Over consumption of sleeping pills may be fatal for the person requiring critical care. Increased psychological and emotional stress is also found to be a major cause of insomnia.
Study Objectives:
The main objective of this research is to provide information about insomnia market in Europe, the Middle East and Africa, its types, drug formulation and type of disease.
- To provide detailed analysis of the market structure along with forecast for the next seven years of the various segments and sub-segments of the insomnia market.
- To provide insights about factors affecting the market growth.
- To analyze the insomnia market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to Europe, Middle East and Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective.
- To provide country level analysis of the market for by types of therapy, drug formulation, by type of diseases and its sub-segments.
- To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
- To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Middle East and Africa insomnia market.
EMEA Insomnia Market Segment Insights
EMEA Insomnia Type Insights
Europe, the Middle East and Africa insomnia market has been segmented on the basis of types of therapy which comprises pharmacological therapy and non-pharmacological therapy. Pharmacological therapy is further segmented into benzodiazepines, non-benzodiazepines, melatonin receptor agonists and other. Non pharmacological treatment are further segmented into relaxation therapy, cognitive behavioural therapy, sleep hygiene education, stimulus control, paradoxical intention and other.
EMEA Insomnia Drug Formulation Insights
By drug formulation they are segmented as capsules, tablet and others.
EMEA Insomnia Disease Insights
On the basis of type of disease they are poor quality of sleep, sleep maintenance and other.
EMEA Insomnia Regional Insights
On regional basis, Europe accounts for accounts the largest share in the Europe, the Middle East and Africa insomnia market. France accounts for the largest market share in insomnia market in Europe. Middle East is the second largest market for insomnia followed by Africa. Increase in prevalence of insomnia, thus resulting in increasing consumption of sleeping pills is the major driving factor for the market in Europe, the Middle East and Africa region.
The report for Europe, the Middle East and Africa insomnia market research report of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
Key Companies in the EMEA Insomnia Market include
- Pfizer Inc. (U.K)
- Sanofi (France)
- GlaxoSmithKline Plc. (UK)
- Astellas (UK)
- Biocodex S A (France)
- Neurim (Switzerland)
- Flynn Pharma (UK)
- CAD Middle East Pharmaceutical Industries LLC (Saudi Arabia)
- Tabuk Pharmaceutical (Jordan)
Intended Audience
- Manufacturing and packaging industries.
- Insomnia devices and drug manufacturers
- Insomnia devices and drug suppliers
- Biotechnology Companies
- Bio-Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Laboratories
- Medical Research Institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
